📊 KLRS Key Takeaways
Is Kalaris Therapeutics, Inc. (KLRS) a Good Investment?
Kalaris is a development-stage biotech company with minimal revenue ($165K) and substantial operating losses (-$46.2M). While the company maintains a strong cash position ($98.1M) with zero debt, the current burn rate of $38.4M annually provides only ~2.5 years of operational runway without reaching meaningful revenue generation. Absent evidence of near-term commercialization or milestone achievement, the risk-reward profile is heavily skewed toward execution failure.
Kalaris is effectively pre-revenue with large operating losses, but it holds a strong, debt-free balance sheet and ample liquidity to fund development for multiple years at the current burn. EPS improvement appears optical given similar net losses, so profitability remains distant without clinical or partnership inflection. Fundamentals warrant patience: balance sheet is solid, but cash burn and execution risks are elevated until revenue visibility emerges.
Why Buy Kalaris Therapeutics, Inc. Stock? KLRS Key Strengths
- Strong liquidity position with $98.1M cash and 12.23x current ratio
- Zero debt, clean balance sheet with manageable liabilities
- Improving operational efficiency trend with EPS improving 94.5% YoY despite losses
- Cash & equivalents ~$98M supporting ~2–3 years of runway at current burn
- Debt-free capital structure (Debt/Equity 0.00x)
- Very strong liquidity (Current/Quick ratio 12.23x)
KLRS Stock Risks: Kalaris Therapeutics, Inc. Investment Risks
- Pre-revenue stage with only $165K annual revenue and -$46.2M operating loss
- Negative operating cash flow of -$38.4M indicates unsustainable burn rate and limited runway
- High-risk biotech sector with significant clinical, regulatory, and commercial execution risk
- No evidence of near-term revenue inflection or commercialization milestones from available data
- Sustained negative FCF and operating losses with minimal revenue
- Financing/dilution risk if timelines slip or burn increases
- Clinical/regulatory execution risk typical of development-stage biotech
Key Metrics to Watch
- Operating cash burn rate and remaining cash runway
- Clinical trial progress and FDA milestone achievements
- Quarterly revenue growth trajectory and commercialization timeline
- Quarterly operating cash burn (OCF)
- Cash & equivalents and implied runway (months)
Kalaris Therapeutics, Inc. (KLRS) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 12.23x current ratio provides a solid financial cushion.
KLRS Profit Margin, ROE & Profitability Analysis
KLRS vs Healthcare Sector: How Kalaris Therapeutics, Inc. Compares
How Kalaris Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kalaris Therapeutics, Inc. Stock Overvalued? KLRS Valuation Analysis 2026
Based on fundamental analysis, Kalaris Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kalaris Therapeutics, Inc. Balance Sheet: KLRS Debt, Cash & Liquidity
KLRS Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kalaris Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-51.77 indicates the company is currently unprofitable.
KLRS Revenue Growth, EPS Growth & YoY Performance
KLRS Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2020 | $165.0K | -$2.5M | N/A |
| Q2 2020 | $165.0K | -$2.5M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kalaris Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
KLRS SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kalaris Therapeutics, Inc. (CIK: 0001754068)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KLRS
What is the AI rating for KLRS?
Kalaris Therapeutics, Inc. (KLRS) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 60% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KLRS's key strengths?
Claude: Strong liquidity position with $98.1M cash and 12.23x current ratio. Zero debt, clean balance sheet with manageable liabilities. ChatGPT: Cash & equivalents ~$98M supporting ~2–3 years of runway at current burn. Debt-free capital structure (Debt/Equity 0.00x).
What are the risks of investing in KLRS?
Claude: Pre-revenue stage with only $165K annual revenue and -$46.2M operating loss. Negative operating cash flow of -$38.4M indicates unsustainable burn rate and limited runway. ChatGPT: Sustained negative FCF and operating losses with minimal revenue. Financing/dilution risk if timelines slip or burn increases.
What is KLRS's revenue and growth?
Kalaris Therapeutics, Inc. reported revenue of $165.0K.
Does KLRS pay dividends?
Kalaris Therapeutics, Inc. does not currently pay dividends.
Where can I find KLRS SEC filings?
Official SEC filings for Kalaris Therapeutics, Inc. (CIK: 0001754068) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KLRS's EPS?
Kalaris Therapeutics, Inc. has a diluted EPS of $-2.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KLRS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kalaris Therapeutics, Inc. has a SELL rating with 60% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KLRS stock overvalued or undervalued?
Valuation metrics for KLRS: ROE of -55.1% (sector avg: 15%), net margin of -26,326.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KLRS stock in 2026?
Our dual AI analysis gives Kalaris Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KLRS's free cash flow?
Kalaris Therapeutics, Inc.'s operating cash flow is $-38.4M, with capital expenditures of $200.0K. FCF margin is -23,375.8%.
How does KLRS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -26,326.1% (avg: 12%), ROE -55.1% (avg: 15%), current ratio 12.23 (avg: 2).